VirtuBiopsy

In today’s medical landscape, biopsy remains an invasive standard procedure, often a source of anxiety and risk for the patient, while representing a significant cost to the healthcare system. The scale of the problem is striking: out of the 3.2 million biopsies performed annually in Europe, clinical literature establishes that approximately 70% ultimately prove unnecessary (negative, inconclusive, or redundant results), generating over €3 billion in avoidable costs and 15 to 20% complication rates. Yet the data needed for a reliable prediction, imaging, genomics, clinical history, already exist in the patient’s medical record. What was missing was the intelligence to read them together. This is the very reason VirtuBiopsy exists.

VirtuBiopsy is the first multimodal artificial intelligence platform designed to predict the histopathological outcome before any invasive procedure. Our proprietary architecture, protected by an INPI patent filed in early 2026, fuses medical imaging, genomic profiles, and clinical patient data to deliver a fully explainable malignancy score. The result is a powerful clinical promise: avoiding up to 70% of unnecessary biopsies without ever compromising the identification of a positive case. With VirtuBiopsy, biopsy ceases to be a systematic reflex and becomes a data-driven decision.

Early results already confirm the robustness of this approach. Our Alpha prototype achieves 72% accuracy on 1,080 real-world breast cancer cases, validating the relevance of multimodal fusion and laying the groundwork for a trajectory of continuous improvement. The technical roadmap targets accuracy above 90% by 2028, the threshold required for CE-MDR Class IIa certification, with deployment initially focused on breast and prostate cancers before extending to lung cancer. This ambition is secured by leading clinical partnerships (AP-HP Paris, Nice University Hospital, and Cannes Hospital) formalized in February 2026, providing access to 5,000 qualified clinical cases for close co-development with hospital practitioners.

By positioning upstream of traditional digital pathology, where no player operates today, VirtuBiopsy opens a “Blue Ocean” market estimated at €4.2 billion in Europe. Our B2B SaaS model, priced between €125 and €250 per analysis, generates €850 in savings per patient for the healthcare system while reducing clinical decision time sixfold. The funding strategy accompanies each stage of maturity: a current pre-seed round of €803K, a €1M Seed raise for multicenter pilot studies, a €4.5M Series A in 2028 for CE-MDR certification and commercialization, followed by a €10M Series B for North American expansion. Profitability is targeted for Q4 2029, with an ARR of €4.1M projected for 2030.

Founded by Dr Majdi Nagara, PhD in artificial intelligence and bioinformatics, patent inventor, and technically led by Salem Janeb (CTO, expert in software architecture and high-performance AI systems), VirtuBiopsy is incubated at IPCA Sophia Antipolis at the heart of the French Riviera’s deeptech ecosystem. Our ambition is clear: to become the global reference in pre-biopsy oncological diagnostics by 2032. By joining VirtuBiopsy, you are not simply funding a startup,  you are accelerating the emergence of a new clinical standard, where every biopsy decision will be guided by data rather than doubt.